China grants 1st COVID-19 vaccine patent to domestic candidate
Chinese authorities have granted the first invention patent to a domestically developed COVID-19 vaccine candidate, which experts said demonstrates the vaccine's originality and creativity and would enhance the international market's trust in Chinese-developed COVID-19 vaccines.
The vaccine, a recombinant adenovirus vaccine named Ad5-nCoV, is co-developed by Chinese biopharmaceutical firm CanSino Biologics Inc., one of the vaccine candidate's co-developers, and a team led by Chinese military infectious disease expert Chen Wei.
According to a document published on China's National Intellectual Property Administration website, the vaccine can be mass-produced in a short time in the event of an outbreak, CGTN reported.
The grant of the patent further confirmed the vaccine's efficacy and safety and convincingly demonstrated the ownership of its intellectual property rights (IPR), CanSino said in a statement on Sunday.
Russian President Vladimir Putin last week announced the development of the world's first vaccine against the novel coronavirus, adding that his daughter had already been vaccinated.